Consistency between value & price is in our access DNA
We are a healthcare consultancy conceiving and rolling out Global and French-setting applied Market Access and Pricing solutions for health technologies. We intervene at all lifecycle stages from earliest R&D stage to post-launch for defining and achieving rewarding market conditions.
From earliest R&D stage to mature commercialization phase
Strategic Access Road Map
Access Conditions and competitive landscape scanning, benchmarking
Target Product Profile definition
Asset profiling (endpoint selection, effectiveness extrapolation, biomarkers, patient subset…)
Value development plans
Clinical and economic value pillar identification, value de-risking Plan (incl. HEOR plan, ATC code..), Payer Evidence Set, Value Dossiers
Price anchoring, Pricing strategies, new Pricing models
With HTA bodies at EU & French levels
With Payers, proxy Payers & KoL
Early & Accelerated Access programs
With HTA body at the EU level
At the French & EU levels
HTA body hearing
Preparation & attendance
Policy definition, negotiation support & contracting insights
Post reimbursement commitment
Real Life value
Drug reimbursement status
For line extension
Renegotiation, price increase, price cut minimization
Asset, pipeline, portfolio value assessement
Value audit of early stage programme
Clinician / Payer Advisory Board for entry into a new therapeutic area
Market Access strategy plan & roll out
Early Access & regular access support
Market Access project management
Asset / portfolio assessment for licensing-in, -out & M&A exercices
Commercial Due diligence
Corporate Market Access & pricing matters
Support to Public Affairs
Internal capabilities building /interim management / board membership
Competition law exercises
Market Access litigations
Support in Patenting
Dr. Véronique Foutel, the consultancy founder, is well acquainted with the scientific and economic evidence requirements of HTA evaluators & payers for both new assets and commercialized drugs and the way to generate this evidence in a timely manner.
Véronique gained this extensive drug market access and pricing experience through various job tenures in the French P&R Autorities, within the Pharma Division of Roche for 16 years, where she led the Global Strategic Pricing function, in the biotech field as Executive Committee Member of a quoted late clinical stage biotech and now as biopharma Strategic Advisor.
Speaker about the drug Market Access conditions in France and in Europe for les Echos Formation, lifescience expert for Bpifrance, Véronique gives master’s degree lectures at Paris Dauphine University.
Former hospital resident of Assistance Publique-Hôpitaux de Paris, Véronique holds a doctorate in Pharmaceutical Sciences from the University Paris V Descartes, and is a graduate of the Executive Health Economics programme of the Stockholm School of Economics and of the Roche Executive Leadership programme of the London Business School.
Development consulting, regulatory affairs, quality management, compliance, pharmacovigilance, epidemiology & risk management worldwide website
Public Health Expertise
High-end life-sciences simulations, data analysis and market-access website
Biometrics & methodological expertise for clinical development activities carried out in pre-, peri- & post-launch website
Medical communication & consultancy website
Medical Communication & consultancy website
Market Access du Médicament en France et Europe – Les Echos Formation
Two-day training course about challenges and opportunities of the Biopharma Industry in France and main EU markets.
Market Access du Médicament en France et en Europe – Les Echos Formation
Two-day training course about the challenges and opportunities of the Biopharma Industry in drug market access in France and main EU markets.